Update shared on 14 Dec 2025
Fair value Increased 2.06%Narrative Update on NeoGenomics
Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook.
What's in the News
- Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).
- New real world data at ASH 2025 will highlight how the Neo Comprehensive Myeloid CGP panel reclassified diagnoses and revealed actionable fusions in about one third of 533 myeloid malignancy cases, informing targeted treatment decisions (company announcement).
- ISLB 2025 research shows 97% concordance between RaDaR ST and RaDaR 1.0 across 15 solid tumor types, validating platform continuity for MRD testing as NeoGenomics advances its NextGen whole genome based MRD program (company announcement).
- Additional ISLB 2025 posters will present validation of the NEO PanTracer LBx liquid biopsy CGP assay and its use in identifying actionable biomarkers in advanced solid tumors, expanding NeoGenomics liquid biopsy and precision oncology footprint (company announcement).
- The company reaffirmed 2025 guidance, targeting revenue of 720 million dollars to 726 million dollars, and projecting a wider net loss of 116 million dollars to 108 million dollars compared with 2024 (company guidance).
Valuation Changes
- The Consensus Analyst Price Target fair value estimate has risen slightly to about 13.44 dollars from roughly 13.17 dollars per share.
- The Discount Rate is essentially unchanged at approximately 6.96 percent, indicating a stable risk and cost of capital assumption.
- Revenue Growth has increased marginally, with the long term annual growth assumption moving from about 9.81 percent to roughly 9.81 percent, rounding to two decimals.
- The Net Profit Margin has edged down slightly, from around 5.47 percent to approximately 5.45 percent, reflecting a modestly more conservative profitability outlook.
- The future P/E multiple has risen slightly, from about 41.4 times to roughly 42.4 times, implying a modestly higher valuation on projected earnings.
Have other thoughts on NeoGenomics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.